Anaphylaxis Emergency Treatment: Epinephrine Dosing and Algorithm

Anaphylaxis is one of the most time-critical emergencies you can encounter in the hospital, office, or prehospital setting. From the onset of initial symptoms to cardiac arrest, only minutes may pass. At the same time, reviews of critical events consistently reveal the same pattern: epinephrine is given too late, at the wrong dose, or via the wrong route of administration. The conclusion is clear — if you want to treat anaphylaxis safely, you need to know the algorithm inside out and have the dosing for adults and children ready to recall at a moment's notice. This article provides you with a systematic review of pathophysiology, severity grading, the concrete treatment algorithm with exact dosing, and the specifics of biphasic reactions.

Pathophysiology in Brief

Anaphylaxis is an acute, systemic hypersensitivity reaction that in most cases is IgE-mediated (type I reaction according to Coombs and Gell). Mast cells and basophilic granulocytes undergo massive degranulation, releasing histamine, tryptase, prostaglandins, leukotrienes, and platelet-activating factor (PAF). Three pathophysiological axes are particularly clinically relevant:

• Vasodilation and increased permeability: Within minutes, up to 35% of intravascular volume can shift into the interstitial space. The resulting distributive shock is the most common cause of death.
• Bronchospasm: Contraction of bronchial smooth muscle, mucosal edema, and hypersecretion lead to severe airway obstruction.
• Cardiac effects: Direct mediator effects on the myocardium can trigger a Takotsubo-like cardiomyopathy or severe arrhythmias (Kounis syndrome).

Understanding these three axes explains why epinephrine is the first-line medication: it acts as a vasoconstrictor via α₁ receptors, as a bronchodilator via β₂ receptors, and as a positive inotrope and chronotrope via β₁ receptors. No other single medication addresses all three pathomechanisms simultaneously.

Severity Grading

The clinical classification of anaphylaxis follows a four-stage model based on the Ring and Messmer classification system. This grading helps you assess urgency and escalate therapy accordingly.

Grade I — Cutaneous Reaction

• Pruritus, flushing, urticaria, angioedema
• No systemic signs
• Close monitoring, allergen avoidance, antihistamines

Grade II — Moderate Systemic Reaction

• In addition to cutaneous symptoms: tachycardia, mild hypotension, early dyspnea, nausea, vomiting
• Intramuscular epinephrine indicated

Grade III — Severe Systemic Reaction (Anaphylactic Shock)

• Bronchospasm, pronounced hypotension (systolic < 90 mmHg), altered level of consciousness
• Life-threatening — immediate aggressive therapy required
• Epinephrine i.m. immediately; if no response, consider i.v. administration

Grade IV — Cardiac Arrest

• Respiratory and/or cardiac arrest
• CPR per AHA algorithm, epinephrine in resuscitation doses

Clinically relevant note: The stages do not necessarily progress sequentially. Anaphylaxis can present directly with shock or airway obstruction without preceding cutaneous symptoms — particularly with parenteral allergen exposure (e.g., intravenous medications, insect stings).

The Treatment Algorithm Step by Step

The following algorithm is based on current recommendations from the AHA, the European Resuscitation Council (ERC), and relevant allergy specialty societies.

Step 1: Recognition and Allergen Removal

• Stop the infusion, remove insect stingers, do not provoke oral allergens
• Document the time of exposure
• Call for help (emergency team, resuscitation team)

Step 2: Intramuscular Epinephrine

Intramuscular epinephrine into the anterolateral thigh (vastus lateralis muscle) is the first-line therapy from Grade II onward. Absorption from the thigh muscle is significantly faster and more reliable than from the deltoid muscle or subcutaneous tissue.

Epinephrine i.m. dosing (concentration 1 mg/ml = 1:1,000):

Patient Group	Dose	Volume (1 mg/ml)
Adults and adolescents > 12 years	0.5 mg	0.5 ml
Children 6–12 years	0.3 mg	0.3 ml
Children 6 months – 6 years	0.15 mg	0.15 ml
Infants < 6 months	0.01 mg/kg body weight	calculate individually

• Repeat every 5 minutes if no clinical improvement
• Up to three i.m. doses before escalating to the intravenous route
• Document the time and dose of each administration

Step 3: Positioning

• Grade II–III without respiratory distress: Trendelenburg position (shock position) with legs elevated approximately 30°
• Predominant respiratory distress/bronchospasm: Upright/seated position
• Pregnant patients: Left lateral decubitus position to avoid inferior vena cava compression syndrome
• Unconscious with spontaneous breathing: Recovery position
• Cardiac arrest: Supine position, begin CPR

Important: Never ask patients with anaphylaxis to stand up or sit up. The abrupt position change in the setting of relative hypovolemia can trigger fatal cardiovascular collapse (so-called "empty ventricle syndrome").

Step 4: Oxygen and Airway Management

• High-flow oxygen via non-rebreather mask (10–15 L/min), target SpO₂ > 94%
• In the presence of stridor or impending airway edema: consider early intubation — an edematous larynx becomes more difficult to intubate with every passing minute
• Nebulized epinephrine (3–5 mg in 5 ml normal saline) for isolated laryngeal edema as a bridging measure
• Prepare a surgical airway (cricothyrotomy) as a last resort

Step 5: Volume Resuscitation

• Large-bore intravenous access (at least 18 G, preferably 16 G), ideally two lines
• Adults: Crystalloid balanced electrolyte solution as a bolus of 500–1000 ml, infused rapidly, repeatable up to 2–4 liters in the first hour
• Children: 20 ml/kg body weight as a bolus over 10–15 minutes, repeatable
• Colloids (particularly HES) are contraindicated in anaphylaxis — they themselves can trigger anaphylaxis

Step 6: Intravenous Epinephrine (for Refractory Anaphylaxis)

If hemodynamic stabilization is not achieved after two to three i.m. doses, intravenous administration is indicated. Intravenous administration mandates hemodynamic monitoring (at minimum continuous ECG and blood pressure monitoring).

Epinephrine i.v. — Adults:

• Bolus: 10–20 µg (= 0.01–0.02 mg) slowly i.v. over 1–2 minutes. Draw up 1 mg epinephrine in 100 ml normal saline (concentration 10 µg/ml) and titrate 1–2 ml at a time.
• Continuous infusion for persistent shock: 0.05–1 µg/kg/min, titrated to blood pressure and heart rate

Epinephrine i.v. — Children:

• Bolus: 1 µg/kg body weight slowly i.v., titrating
• Continuous infusion: 0.1–1 µg/kg/min

Common critical error: Concentration mix-ups. The i.m. dose uses the 1:1,000 solution (1 mg/ml), while the i.v. bolus dose uses the 1:100,000 dilution (10 µg/ml). Accidental i.v. administration of undiluted 1:1,000 solution can cause lethal arrhythmias or hypertensive crisis. Clear labeling and double-checking (four-eyes principle) are essential.

Step 7: Adjunctive Medications

The following medications are second-line therapy — they do not replace epinephrine but support the treatment:

Antihistamines:

• H₁ blocker: Dimetindene (Fenistil®) 0.1 mg/kg body weight i.v. (adults: 4–8 mg)
• H₂ blocker: Ranitidine 50 mg i.v. or famotidine 20 mg i.v.
• The combination of H₁ + H₂ is superior to monotherapy

Glucocorticoids:

• Methylprednisolone 1–2 mg/kg body weight i.v. or prednisolone equivalent
• Onset of action not until 4–6 hours — not an acute medication!
• Primary indication: prophylaxis of biphasic reactions (evidence for this is limited, however)

Bronchospasm treatment:

• Nebulized salbutamol: 2.5–5 mg via nebulizer for persistent bronchospasm
• Ipratropium bromide 0.5 mg nebulized as add-on for inadequate response to β₂ agonists

Vasopressin analogs for catecholamine-refractory shock:

• Vasopressin 1–2 IU as a bolus, then 0.01–0.04 IU/min as a continuous infusion
• Methylene blue (1–2 mg/kg i.v. over 20 minutes) as rescue therapy for treatment-refractory vasodilation — case reports demonstrate efficacy

Glucagon:

• Indication: patients on beta-blocker therapy with inadequate response to epinephrine
• Dose: 1–5 mg i.v. over 5 minutes, then 5–15 µg/min as infusion
• Acts via a catecholamine-independent mechanism as a positive inotrope and chronotrope

Special Considerations in Children

Anaphylaxis treatment in children follows the same algorithm but requires special attention:

• Weight-based dosing is mandatory for all medications — emergency length-based tapes or apps (e.g., PedAMINES) reduce dosing errors
• Hypotension presents late in children — tachycardia and behavioral changes (agitation, drowsiness) are earlier warning signs
• Consider intraosseous (i.o.) access early if peripheral venous access is not established within 60–90 seconds
• Epinephrine auto-injectors for children weighing 15–30 kg contain 0.15 mg; from 30 kg onward, 0.3 mg

Biphasic Reactions: The Underestimated Danger

Biphasic anaphylaxis occurs in approximately 5–20% of cases. After initial clinical improvement, symptoms recur — typically within 1–72 hours, with a peak incidence at 8–12 hours after the initial event.

Risk Factors for Biphasic Reactions

• Severe initial reaction (Grade III–IV)
• Delayed or inadequate epinephrine administration during the initial reaction
• Need for more than one dose of epinephrine
• Unknown or non-eliminable allergen
• Anaphylaxis triggered by orally ingested allergens (delayed absorption)

Consequence: Observation Period

Current recommendations advise the following minimum observation periods:

• Grade I: at least 4–6 hours
• Grade II–III with rapid response to a single dose of epinephrine: at least 6–8 hours
• Grade III with multiple epinephrine doses, hemodynamic instability, or known risk factors: at least 24 hours of inpatient monitoring
• Grade IV (resuscitation): intensive care unit admission mandatory

During the observation period, continuous monitoring (ECG, SpO₂, non-invasive blood pressure), an indwelling venous access, and immediately available epinephrine are essential.

Documentation and Follow-Up Care

Every anaphylactic reaction requires thorough documentation and follow-up:

• Tryptase measurement: Blood draw ideally 1–2 hours after symptom onset, plus a baseline value at 24 hours. Elevated tryptase objectively confirms mast cell activation and has both differential diagnostic and medicolegal significance.
• Allergy passport: If the triggering allergen is known or suspected, a preliminary allergy passport should be issued and referral for allergological workup arranged.
• Epinephrine auto-injector prescription: Every patient after a systemic anaphylactic reaction (≥ Grade II) should be discharged with at least two epinephrine auto-injectors and a written anaphylaxis emergency action plan.
• Training: Patients and family members must receive hands-on training in auto-injector use — verbal instruction alone has been proven insufficient.

Common Errors in Practice

Finally, here is a summary of the most common avoidable errors consistently identified in reviews of anaphylactic incidents:

1. Epinephrine is not given or given too late — often due to fear of side effects. With correct i.m. dosing, the risk-benefit ratio clearly favors administration.
2. Wrong injection site: Subcutaneous injection or injection into the deltoid muscle leads to unreliable absorption.
3. Concentration mix-up during i.v. administration (1:1,000 instead of 1:100,000).
4. Exclusive administration of antihistamines and corticosteroids without epinephrine — these medications alone do not adequately treat either the shock or the bronchospasm.
5. Premature discharge without an adequate observation period.
6. Sitting up or standing up patients after apparent improvement.
7. Lack of follow-up care: No tryptase measurement, no allergy passport, no auto-injector prescription.

Hands-On Training

Anaphylaxis is an emergency where seconds count and dosing errors can have fatal consequences. Theoretical knowledge alone is not enough — the safe application of the algorithm, the rapid preparation and correct dilution of epinephrine, and team communication under stress must be practiced regularly in a hands-on setting. In the emergency training courses by Simulation Tirol, you practice exactly these scenarios in a realistic simulation environment, receive direct feedback, and solidify the workflows that save lives in a real emergency.

---